First randomized evaluation of safety, pharmacodynamics, and pharmacokinetics of BAY 1831865, an antibody targeting coagulation factor XI and factor XIa, in healthy men

First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

(2021) Dirk Thomas et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Abelacimab for Prevention of Venous Thromboembolism

(2021) Peter Verhamme et al.   NEW ENGLAND JOURNAL OF MEDICINE

Milvexian, an orally bioavailable, small‐molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits

(2021) Pancras C. Wong et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Milvexian for the Prevention of Venous Thromboembolism

(2021) Jeffrey I. Weitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

Novel antithrombotic strategies for treatment of venous thromboembolism

(2020) Jeffrey I. Weitz et al.   BLOOD

How Effective and Safe Is Factor XI Inhibition in Preventing Venous Thrombosis?

(2020) Kenneth A. Bauer   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty

(2020) Jeffrey I. Weitz et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans

(2019) Alexander W. Koch et al.   BLOOD

A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding

(2019) Rami A. Al‐Horani et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

First-in-human study to assess the safety, pharmacokinetics and pharmacodynamics of BMS-962212, a direct, reversible, small molecule factor XIa inhibitor in non-Japanese and Japanese healthy subjects

(2018) Vidya Perera et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Recent advances in the discovery and development of factor XI/XIa inhibitors

(2018) Rami A. Al-Horani et al.   MEDICINAL RESEARCH REVIEWS

Factor 11 single-nucleotide variants in women with heavy menstrual bleeding

(2017) Sophie Wiewel-Verschueren et al.   JOURNAL OF OBSTETRICS AND GYNAECOLOGY

Generation and characterization of aptamers targeting factor XIa

(2017) R.S. Woodruff et al.   THROMBOSIS RESEARCH

Factor XI as a Therapeutic TargetHighlights

(2016) David Gailani et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Gynaecological and obstetrical bleeding in women with factor XI deficiency - a systematic review

(2015) S. Wiewel-Verschueren et al.   HAEMOPHILIA

Factor XI and contact activation as targets for antithrombotic therapy

(2015) D. Gailani et al.   JOURNAL OF THROMBOSIS AND HAEMOSTASIS

Factor XI Antisense Oligonucleotide for Prevention of Venous Thrombosis

(2015) Harry R. Büller et al.   NEW ENGLAND JOURNAL OF MEDICINE

Allosteric Inhibition of Human Factor XIa: Discovery of Monosulfated Benzofurans as a Class of Promising Inhibitors

(2014) Malaika D. Argade et al.   JOURNAL OF MEDICINAL CHEMISTRY

Designing Allosteric Inhibitors of Factor XIa. Lessons from the Interactions of Sulfated Pentagalloylglucopyranosides

(2014) Rami A. Al-Horani et al.   JOURNAL OF MEDICINAL CHEMISTRY

Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

(2010) Ron J. Keizer et al.   CLINICAL PHARMACOKINETICS